sales
Allergan launches Crestor generic in the US
May 3, 2016Manufacturing and Production, Research and Development, Sales and Marketing Allergan, AstraZeneca, Crestor, FDA, FDA Approval, cholesterol, generic, patent, patent expiry, sales
Allergan has received FDA approval on the generic version of AstraZeneca’s high cholesterol drug, Crestor (rosuvastatin), and has become the …
Mylan Q1 revenue up 17%, maintains FY view
May 3, 2016Manufacturing and Production, Sales and Marketing Financial, Mylan, Q1, results, revenue, sales
Pharma firm Mylan NV (Nasdaq: MYL) on Tuesday reported a 17% rise in first-quarter revenue and said it maintains its …
GlaxoSmithKline Q1 earnings up 14% on new product sales
April 27, 2016Research and Development, Sales and Marketing GSK, GlaxoSmithKline, Q1, earnings, results, revenue, sales
GlaxoSmithKline (LSE: GSK) reported a 14% rise in first-quarter earnings driven by demand for new drugs. The UK drug firm …
Eli Lilly Q1 earnings miss estimates, ups FY view; shares drop 2%
April 27, 2016Research and Development, Sales and Marketing Eli Lilly, FY, Q1, earnings, revenue, sales
Shares in US drugmaker Eli Lilly (NYSE: LLY) dropped to close down over 2% Tuesday after the company posted first-quarter …
AstraZeneca sells US rights for gout treatment to Ironwood Pharmaceuticals
April 27, 2016Research and Development, Sales and Marketing AstraZeneca, Ironwood, Licencing, Zurampic, agreement, exclusive, gout, lesinurad, sales
AstraZeneca (LSE: AZN) has entered into a licencing agreement with Ironwood Pharmaceuticals (NASDAQ: IRWD) which will see the latter granted …
Bayer’s earnings beat estimates as blockbusters shine
April 26, 2016Manufacturing and Production, Research and Development, Sales and Marketing Bayer, Eylea, Q1, Xarelto, blockbusters, growth, results, sales
Bayer (FWB: BAYN) has reported a 15.7% rise in underlying core earnings for the first quarter of 2016, with prescription …
Focus: Bristol-Myers Squibb’s wonder drug – Opdivo
April 20, 2016Research and Development, Sales and Marketing BMS, growth, immuno-oncology, opdivo, sales
By Anjali ShuklaNew data for Bristol-Myers Squibb’s (NYSE: BMY) Opdivo to treat head and neck cancer showed superior survival compared with …
J&J raises FY outlook, Q1 beats estimates
April 20, 2016Business Services, Research and Development, Sales and Marketing Financial, Johnson & Johnson, Q1, earnings, results, revenue, sales
Healthcare giant Johnson & Johnson (NYSE: JNJ) raised its full-year outlook and posted first-quarter earnings ahead of estimates despite currency headwinds. …
Federal jury rules in MSD’s favour in Gilead blockbuster hepatitis C drug dispute
March 23, 2016Medical Communications, Research and Development Gilead, MSD, blockbuster, federal court, federal jury, hit, patents, sales, sales hit, sofosbuvir, sovaldi
Gilead’s dominance of the hepatitis C market is under severe threat after a federal jury ruled in favour of MSD …
Revenues down at MSD
February 4, 2016Sales and Marketing MSD, financial performance, profits, revenue, sales
MSD (Merck, Sharpe and Dohme) reported a mixed bag of financial figures today, as the company announced full-year 2015 revenues …
Revealed: analysts predict seven highest-earning pharma blockbusters
February 4, 2016Sales and Marketing Gilead, OCA, Thomson Reuters, blockbusters, sales
Seven new drugs currently in development will enter the market this year – and earn sales of more than $1 …
Pfizer revenues down, but above expectations
February 3, 2016Research and Development, Sales and Marketing Ian Read, Pfizer, financial results, income, profits, revenue, sales
Pfizer’s revenues took a hit from generic competition on former blockbusters, but the world’s new largest drugmaker still managed to …
Novartis braces for cuts after mixed 2015 performance
January 28, 2016Sales and Marketing Novartis, financial results, revenue, sales
Net sales at Novartis fell by 5% in 2015 – prompting the company to make billion-dollar changes to its business …
Johnson & Johnson hit by fall in 2015 sales
January 27, 2016Research and Development, Sales and Marketing Janssen, Johnson and Johnson, financial results, revenue, sales
Full year sales at the healthcare giant Johnson & Johnson fell by 6% in 2015, to just over $70 billion, …
Takeda to bring UK salesforce in-house
January 15, 2016Medical Communications, Sales and Marketing Takeda, field sales, marketing, sales, sales reps, salesforce
Takeda UK is to bring all of its sales teams and support resources in-house and reintegrate its field salesforce into …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
